These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133 [TBL] [Abstract][Full Text] [Related]
3. Safety of revaccination with pneumococcal polysaccharide vaccine. Jackson LA; Benson P; Sneller VP; Butler JC; Thompson RS; Chen RT; Lewis LS; Carlone G; DeStefano F; Holder P; Lezhava T; Williams WW JAMA; 1999 Jan; 281(3):243-8. PubMed ID: 9918479 [TBL] [Abstract][Full Text] [Related]
4. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Mufson MA; Hughey DF; Turner CE; Schiffman G Vaccine; 1991 Jun; 9(6):403-7. PubMed ID: 1887670 [TBL] [Abstract][Full Text] [Related]
5. Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia. Kaplan J; Sarnaik S; Schiffman G Am J Pediatr Hematol Oncol; 1986; 8(1):80-2. PubMed ID: 3717518 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B; Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493 [TBL] [Abstract][Full Text] [Related]
7. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Snow R; Babish JD; McBean AM Public Health Rep; 1995; 110(6):720-5. PubMed ID: 8570826 [TBL] [Abstract][Full Text] [Related]
9. Leads from the MMWR. Recommendations of the Immunization Practices Advisory Committee. Pneumococcal polysaccharide vaccine. JAMA; 1989 Mar; 261(9):1265-7. PubMed ID: 2644464 [No Abstract] [Full Text] [Related]
10. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Hilleman MR; Carlson AJ; McLean AA; Vella PP; Weibel RE; Woodhour AF Rev Infect Dis; 1981; 3 Suppl():S31-42. PubMed ID: 7025159 [TBL] [Abstract][Full Text] [Related]
11. The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study. Doherty K; Bonnett L; Agbla SC; Beveridge NER; Decraene V; Fleming KM; Hungerford D; French N Vaccine; 2024 Sep; 42(22):126002. PubMed ID: 38796329 [TBL] [Abstract][Full Text] [Related]
12. Pneumococcal vaccine in children and young adults with chronic renal disease. Fuchshuber A; Kühnemund O; Keuth B; Lütticken R; Michalk D; Querfeld U Nephrol Dial Transplant; 1996 Mar; 11(3):468-73. PubMed ID: 8671817 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165 [TBL] [Abstract][Full Text] [Related]
15. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583 [TBL] [Abstract][Full Text] [Related]
17. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024 [TBL] [Abstract][Full Text] [Related]
18. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review. Remschmidt C; Harder T; Wichmann O; Bogdan C; Falkenhorst G BMC Infect Dis; 2016 Nov; 16(1):711. PubMed ID: 27887596 [TBL] [Abstract][Full Text] [Related]